zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2023 / The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.

The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.

2023-10-02

Published Date:2023-10-02

Original Link:https://www.onenessbio.com/en/news_detail245_2.htm

No 1 Date of announcement 2023/10/02 Time of announcement  16:52:23
Subject The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD
To which item it meets paragraph 12 Date of events 2023/10/03
Statement
  1. Date of institutional investor conference:2023/10/03
  2. Time of institutional investor conference:16:45 (TPE time)
  3. Location of institutional investor conference:Hamburg, Germany
  4. Outline of institutional investor conference:
    (1)The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.
    (2)The European Association for the Study of Diabetes (EASD) has been established since 1965. The EASD Annual Meeting has been one of the largest and most reputable scientific congress on diabetes in Europe.The congress covers diabetes-related researches and focuses in the important progress of fundamental science, prevention, diagnosis and treatments in diabetes.
  5. Any other matters that need to be specified:The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation.